Clinical trials: Advanced Hepatocellular Carcinoma
Advanced Malignant Solid Neoplasm, Advanced Biliary Tract Carcinoma
Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer
This phase II trial tests how well olanzapine works in managing cancer cachexia in patients experiencing esophagogastric, hepatopancreaticobiliary, colorectal, or lung cancer that may have spread from where it first started to…
- Conditions
- Advanced Malignant Solid Neoplasm, Advanced Biliary Tract Carcinoma, Advanced Esophageal Carcinoma, Metastatic Esophageal Carcinoma
- Trial name
- NCT05705492
- Testing
- Olanzapine, Questionnaire Administration
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- OHSU Knight Cancer Institute
Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma
Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
This is a Phase 1/1b, open-label, first-in-human, dose-escalation and expansion study of CHS-388, a monoclonal antibody that targets IL-27, as a monotherapy and in combination in patients with solid tumors.
- Conditions
- Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT04374877
- Testing
- CHS-388, Pembrolizumab, Toripalimab
- Where
- 23 sites in United States, Singapore and 1 more
- Volunteers
- 145 people
- Sponsor
- Coherus Oncology, Inc.
Advanced Hepatocellular Carcinoma (HCC)
Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC
This is a prospective, randomized, open-label, parallel-group, active controlled, multi-center phase III registration clinical study to observe, compare and evaluate the efficacy and safety of Toripalimab (hereafter referred to…
- Trial name
- NCT04723004
- Testing
- Toripalimab combined with Bevacizumab, Sorafenib
- Where
- 56 sites in China, Singapore
- Volunteers
- 326 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Advanced Hepatocellular Carcinoma (HCC)
A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripalimab Injection (JS001) Combined With Bevacizumab as the First-line Therapy for Advanced Hepatocellular Carcinoma (HCC)
This is an open-label, single-arm, national multicenter phase II clinical study to preliminarily observe and evaluate the efficacy and safety of Toripalimab combined with Bevacizumab as the first-line therapy for advanced HCC The…
- Trial name
- NCT04605796
- Testing
- Toripalimab combined with Bevacizumab
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Hepatitis C Virus Infection, Compensated Advanced Chronic Liver Disease
Non-Invasive Risk Stratification for Hepatocellular Carcinoma in HCV-Related Compensated Advanced Chronic Liver Disease Following Sustained Virological Response: Validation of the aMAP Score
This retrospective cohort study evaluated the performance of non-invasive risk scores for predicting de novo hepatocellular carcinoma in adults with hepatitis C virus-related compensated advanced chronic liver disease who…
- Conditions
- Hepatitis C Virus Infection, Compensated Advanced Chronic Liver Disease, Hepatocellular Carcinoma (HCC)
- Trial name
- HCV-aMAP (NCT07687758)
- Testing
- Non-invasive Risk Score Assessment
- Where
- Thailand
- Volunteers
- 571 people
- Sponsor
- Siriraj Hospital
Advanced Hepatocellular Carcinoma (HCC)
Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCC
This is a prospective, randomized, placebo-controlled, double-blind, multicenter phase III registration clinical study to observe, compare and evaluate the efficacy and safety of Toripalimab combined with Lenvatinib versus…
- Trial name
- NCT04523493
- Testing
- Toripalimab combined with Lenvatinib
- Where
- 22 sites in China, Italy and 3 more
- Volunteers
- 530 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
PET-CT in Determining the Radioembolization Dose Delivered to Patients With Liver Metastasis, Primary Liver Cancer, or Biliary Cancer
This clinical trial studies positron emission tomography (PET)-computed tomography (CT) in determining the radiation dose delivered with radioactive spheres to patients with liver metastasis or primary liver or biliary cancer.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Metastatic Extrahepatic Bile Duct Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT02088775
- Testing
- PET scan, CT Scan, hepatic artery embolization
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Fox Chase Cancer Center
Advanced Hepatocellular Carcinoma
Durvalumab for Advanced Hepatocellular Carcinoma in Patients With Active Chronic Hepatitis B Virus Infection
PD1 blockade has been approved as salvage therapy for advanced hepatocellular carcinoma (HCC). Although there is not solid evidence that PD1 blockade would induce hepatitis B virus (HBV) reactivation, previous clinical trials of…
- Trial name
- NCT04294498
- Testing
- Durvalumab
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- National Taiwan University Hospital
Advanced Hepatocellular Carcinoma
Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)
The purpose of this study is to evaluate the safety and efficacy of fixed dose coformulated pembrolizumab/quavonlimab (MK-1308A) plus lenvatinib in a first line (1L) hepatocellular carcinoma (HCC) setting.
- Trial name
- NCT04740307
- Testing
- Pembrolizumab/Quavonlimab, Lenvatinib, Pembrolizumab
- Where
- 40 sites in United States, China and 7 more
- Volunteers
- 116 people
- Sponsor
- Merck Sharp & Dohme LLC
Locally Advanced or Metastatic Hepatoceullar Carcinoma
Comparison of Atezolizumab/Bevacizumab Versus Durvalumab/Tremelimumab (STRIDE) Protocols in Locally Advanced or Metastatic Hepatocellular Carcinoma Among Patients in Sohag
This retrospective observational study compares two first-line immunotherapy-based treatment regimens used for adults with locally advanced or metastatic hepatocellular carcinoma (HCC) at Suhag Cancer Center, Egypt.
- Trial name
- HCC (NCT07669597)
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Sohag Oncology Center
Advanced Adult Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
This randomized phase III trial studies sorafenib tosylate and doxorubicin hydrochloride to see how well they work compared with sorafenib tosylate alone in treating patients with liver cancer that has spread to nearby tissue or…
- Conditions
- Advanced Adult Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v7, Stage IIIA Hepatocellular Carcinoma AJCC v7
- Trial name
- NCT01015833
- Testing
- Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Pharmacogenomic Study
- Where
- 673 sites in United States, Canada and 1 more
- Volunteers
- 356 people
- Sponsor
- National Cancer Institute (NCI)
Cirrhosis, Liver, Advanced Liver Fibrosis
Erlotinib for Hepatocellular Carcinoma Chemoprevention
This phase II randomized placebo-controlled trial studies low-dose erlotinib treatment to assess its efficacy and safety to prevent development of hepatocellular carcinoma in patients with advanced liver fibrosis or cirrhosis.
- Trial name
- ECHO-B (NCT04172779)
- Testing
- erlotinib hydrochloride
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Texas Southwestern Medical Center
Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Melanoma Neoplasms
Evaluation of Skin Tests in Biotherapy Allergies
Biotherapies are biological (extracted from an organism or living tissue) or biotechnological drugs used in the treatment of multiple conditions, such as autoimmune inflammatory diseases, cancers, and hematologic diseases.
- Conditions
- Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Melanoma Neoplasms, Small Cell Bronchial Carcinomas, Bronchial Carcinoma
- Trial name
- ETCABIO (NCT06971848)
- Testing
- Drug skin tests (investigating hypersensitivity to a biotherapy)
- Where
- France
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- University Hospital, Angers
Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
The purpose of the dose escalation part of the study is to characterize the safety and tolerability of ALN-BCAT as monotherapy and in combination with pembrolizumab; and to determine the recommended dose(s) for expansion (RDFE)…
- Trial name
- NCT06600321
- Testing
- ALN-BCAT, Pembrolizumab
- Where
- 23 sites in United States, Italy and 1 more
- Volunteers
- 158 people
- Sponsor
- Alnylam Pharmaceuticals
Advanced or Unresectable Hepatocellular Carcinoma (HCC)
A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
This is a randomized, open-label, multicenter Phase Ib/II registration trial designed to evaluate the efficacy and safety of HH-009 in patients with FGF19-positive hepatocellular carcinoma (HCC).
- Trial name
- NCT07547553
- Testing
- Will receive HH-009 injection 20 mg/kg, Q3W, Will receive HH-009 injection 30 mg/kg, Q3W
- Where
- 21 sites in China
- Volunteers
- 30 people
- Sponsor
- Huahui Health
Cancer (Advanced Stage)
Pilot Study of Intermittent Fasting With Immune Checkpoint Inhibitors
This single-site, randomized pilot study will evaluate whether intermittent fasting is feasible and safe for patients with advanced solid tumors who are starting immune checkpoint inhibitor (ICI) therapy at the WVU Cancer…
- Trial name
- NCT07645742
- Testing
- Alternate-Day Fasting (ADF), Time-Restricted Eating (TRE)
- Volunteers
- 90 people
- Sponsor
- West Virginia University
Advanced Hepatocellular Carcinoma
A Study of Cadonilimab Combined With Regorafenib in Patients With Advanced HCC
To evaluate the efficacy and safety of cadonilimab combined with regorafenib in patients with HCC who progressed on systemic therapy.
- Trial name
- NCT05773105
- Testing
- Cadonilimab+regorafenib
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Sun Yat-sen University
Advanced Hepatocellular Carcinoma
A Study of BL-B01D1 Monotherapy, BL-B01D1 in Combination With Lenvatinib, BL-B01D1 in Combination With PD-1 Monoclonal Antibody, and BL-B01D1 in Combination With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma
This study is a clinical study to explore the efficacy and safety of BL-B01D1 monotherapy, BL-B01D1 in combination with lenvatinib, BL-B01D1 in combination with PD-1 monoclonal antibody, and BL-B01D1 in combination with PD-1…
- Trial name
- NCT06986785
- Testing
- BL-B01D1, Lenvatinib, Finotonlimab
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Advanced Neoplasms
Study of E7386 in Participants With Selected Advanced Neoplasms
This study will be conducted to assess the safety/tolerability profile of E7386 as a single agent administered orally in participants with selected advanced or recurrent neoplasms and to determine the maximum tolerated dose (MTD)…
- Trial name
- NCT03264664
- Testing
- E7386
- Where
- 10 sites in United States, United Kingdom
- Volunteers
- 60 people
- Sponsor
- Eisai Inc.
Advanced Solid Tumors, Ewing Sarcoma
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
A Phase 1/1B Study of ST-01156 in Patients with Advanced Solid Malignancies
- Conditions
- Advanced Solid Tumors, Ewing Sarcoma, Hepatocellular Carcinoma (HCC), Biliary Tract Cancer (BTC)
- Trial name
- NCT07197554
- Testing
- ST-01156
- Where
- 6 sites in United States
- Volunteers
- 171 people
- Sponsor
- SEED Therapeutics, Inc.